Cover Image

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: results of the EWOG-MESRAT study

EWOG-MESRAT (European Working Group—Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator-initiated trial that studied EPIC array-based DNA methylation patterns and next generation sequencing (NGS)-based variant allele frequencies (VAFs) of driver mutations in...

Full description

Saved in:
Bibliographic Details
Main Authors: Schönung, Maximilian (Author) , Rathmann, Silvia (Author) , Ramamoorthy, Senthilkumar (Author) , Lebrecht, Dirk (Author) , Klingebiel, Thomas (Author) , Locatelli, Franco (Author) , Nysom, Karsten (Author) , Rossig, Claudia (Author) , Starý, Jan (Author) , Zecca, Marco (Author) , Patturajan, Meera (Author) , Erlacher, Miriam (Author) , Strahm, Brigitte (Author) , Niemeyer, Charlotte M. (Author) , Lipka, Daniel (Author) , Flotho, Christian (Author)
Format: Article (Journal)
Language:English
Published: 31 July 2025
In: British journal of haematology
Year: 2025, Volume: 207, Issue: 4, Pages: 1271-1278
ISSN:1365-2141
DOI:10.1111/bjh.70046
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/bjh.70046
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.70046
Get full text
Author Notes:Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, Dirk Lebrecht, Thomas Klingebiel, Franco Locatelli, Karsten Nysom, Claudia Rossig, Jan Starý, Marco Zecca, Meera Patturajan, Miriam Erlacher, Brigitte Strahm, Charlotte M. Niemeyer, Daniel B. Lipka, Christian Flotho
Description
Summary:EWOG-MESRAT (European Working Group—Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator-initiated trial that studied EPIC array-based DNA methylation patterns and next generation sequencing (NGS)-based variant allele frequencies (VAFs) of driver mutations in peripheral blood (PB) and bone marrow (BM) of 11 patients with newly diagnosed juvenile myelomonocytic leukaemia (JMML) during therapy with azacitidine. We demonstrate that the pharmacodynamic activity of azacitidine can efficiently be monitored in PB and BM. DNA methylation subgroup classification was linked to clinical response after three cycles of azacitidine and found to be conserved between PB and BM in all patients. In contrast, neither changes in VAFs nor changes in DNA methylation patterns during the course of therapy correlated with therapy outcome among the 11 study patients. This work thus supports the value of DNA methylation subgroup classification from PB samples for response prediction of single-agent azacitidine in patients with JMML.
Item Description:Gesehen am 16.12.2025
Physical Description:Online Resource
ISSN:1365-2141
DOI:10.1111/bjh.70046

Similar Items